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Abstract
Post-approval changes are inevitable and necessary throughout the lifecycle of
pharmaceutical products to implement new knowledge, maintain a state of control, and
drive continual improvement.
This One-Voice-of-Quality (1VQ) position paper is part of a series of industry case studies
intended to demonstrate the standard application of the principles outlined in the
publication “Effective Management of Post-Approval Changes in the Pharmaceutical Quality
System (PQS) - Through Enhanced Science and Risk-Based Approaches Industry; One-Voiceof-Quality (1VQ) Solutions” in PDA Journal of Pharmaceutical Science and Technology, 2020
[1].
Furthermore, this 1VQ position paper provides a practical application of the concepts
described in ICH Q9, Quality Risk Management [2], ICH Q10, Pharmaceutical Quality System
[3], and ICH Q12, Technical and Regulatory Considerations for Pharmaceutical Product
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Lifecycle Management [4] to changes to analytical equipment/instrumentation that are
deemed to be equivalent.
In this case study, the risk associated with the extension of shelf-life was evaluated. The
conclusion drawn is that shelf-life extension changes when controlled effectively as
described in this paper, present a low risk to product quality, and therefore can be
downgraded from a prior-approval to notification or annual reportable and managed in the
PQS with immediate implementation.
KEYWORDS
CMC, Chemistry Manufacturing and Control, Regulatory, Post-approval Change, PAC, ICH
Q9, Quality Risk Management, QRM, ICH Q10, Pharmaceutical Quality System, PQS, ICH
Q12, Lifecycle Management, Change Control, Regulatory Considerations, Regulatory
Flexibility, Science and Risk-based Approach, One-Voice-Of-Quality, Shelf-life Extensions,
Pharmaceutical Products.

BACKGROUND AND CONTEXT
ICH Q10, Pharmaceutical Quality System, Annex 1 describes potential opportunities to
enhance science and risk-based regulatory approaches to PACs as follows: When a company
can “demonstrate effective PQS and product and process understanding” this is an
opportunity to “optimize science and risk-based PAC processes to maximize benefits from
innovation and continual improvement” [3]. Current regulatory mechanisms and guidance
for PACs do not consider the company’s latest product and process knowledge when
determining the type of filing required to implement the change. Further, the application of
ICH Q9, Quality Risk Management, or the effectiveness of the company’s PQS to manage
PACs is not considered during the assessment of individual PACs or during inspections.
Demonstrating a detailed understanding, effective implementation, and compliance with
ICH Q10, will allow companies to overcome barriers to continual improvement and
innovation. Additionally, it will help reduce drug shortages in the global environment by
allowing faster implementation of PACs and reducing the PAC burden on both industry and
regulators.
This specific example of shelf-life extension for pharmaceutical products demonstrates the
application of the principles outlined in ICH Q9, Q10, Q12 irrespective of current national or
regional reporting category and concludes that it can be managed as a notification with
2
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immediate implementation effect. It is acknowledged that different companies might be
handling this example differently and may not need to pursue a regulatory downgrade for
this PAC. However, companies that file this as a prior approval change, may use this
position paper as a starting basis and modify scope and relevant considerations for their
specific need and in accordance with their company’s PQS requirements.
This PAC example and the 1VQ work in general is sponsored by the Chief Quality Officer’s
from more than 20 pharmaceutical companies [5].
DESCRIPTION OF CURRENT STATE FOR SHELF-LIFE EXTENSIONS FOR PHARMACEUTICAL
PRODUCTS
Regulatory authority notification or prior approval with long waiting periods is required in
most countries for changes associated with shelf-life extensions for pharmaceutical
products, even when there are no changes to the product quality, patient safety or drug
product efficacy, and the formulation, manufacturing and laboratory controls remain the
same, and there are no changes to the stability acceptance criteria (refer to Table 1).
In certain cases, drug shortage situations that could have been avoided if a product with a
longer shelf-life was available in the supply chain, is hindered by the manufacturer’s inability
to extend the shelf-life using product and process knowledge, sound scientific and riskbased assessment principles without prior regulatory approval.
The initial pharmaceutical product regulatory registration dossier is typically based on
information and supporting data described in ICH M4Q CTD Quality Module 3. The product
shelf-life with the supporting stability data is submitted for review and approval to the
concerned regulatory authorities. In most cases, the concerned regulatory authority grants
the applicant’s initial drug product shelf-life request as conditional approval with a
commitment to continue ongoing stability monitoring and provide updates as part of a postapproval commitment. The applicant then provides full stability report and supporting data
to cover the entire approved shelf life of both the drug substance and drug product. An
applicant based on the ongoing stability data, may request an extension of the product shelf
life later as a post-approval change, and submit the required supporting information.
The table below lists the current regulatory reporting categories for shelf-life extensions of
pharmaceutical products in different countries.
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Table 1: Current Regulatory Reporting Categories for Pharmaceutical Products Shelf-Life
Extension in ICH, PIC/S and WHO member countries
Country

Annual
Reportable

Notification Minor Variation for

Major Variation

EU countries- Type 1B

for EU Countries

or a ‘Prior Approval

– Type II or Prior-

’ for all other

Approval

countries
1. WHO*

x

2. Argentina

x

3. Armenia

x

4. Australia

x

5. Austria

x

6. Belgium

x

7. Brazil

x

8. Canada

x

9. China

x

10. Colombia

x

11. Cuba

x

12. Croatia

x

13. Cyprus

x

14. Czech Republic

x

15. Denmark

x

16. Estonia

x

17. European Union

x

18. Finland

x

19. France

x

20. Germany

x

21. Greece

x

22. Greenland

x

23. Hong

Kong

(SAR,

x
4
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China)
24. Hungary

x

25. Iceland

x

26. India

x

27. Indonesia

x

28. Iran

x

29. Ireland

x

30. Israel

x

31. Italy

x

32. Japan

x

33. Jordan

x

34. Kazakhstan

x

35. Latvia

x

36. Liechtenstein

x

37. Lithuania

x

38. Malaysia
39. Malta

x
x

40. Mexico

x

41. Moldova

x

42. Netherlands

x

43. New Zealand

x

44. Norway

x

45. Poland

x

46. Portugal

x

47. Russian Federation
48. Romania

x
x

49. Saudi Arabia

x

50. Singapore

x

51. Slovakia

x

52. Slovenia

x

53. South Africa

x
5
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54. South Korea

x

55. Spain

x

56. Sweden

x

57. Switzerland

x

58. Taiwan

(Chinese

x

Taipei)
59. Thailand

x

60. Turkey

x

61. Ukraine
62. United Kingdom
63. United States**

x

x

x

*World Health Organization ((WHO) - Commercial drug products can be registered via WHO
procedures in Botswana, Burkina Faso, Cameroon, Congo, Cote D’Ivore, Malawi, Namibia,
Senegal, Tanzania, Uganda, Zambia, Zimbabwe, etc.
**United States - Annual Reportable, only when there is an approved stability protocol for
shelf-life extension
The following are representative pharmaceutical industry specific examples that summarize
the current state of shelf-life extensions:
Industry Case 1:
•

Product: Oral Solid Dosage Form 0.25mg 28ct bottle; 2mg bottle 30ct; 0.25mg
Starter Pack (count)

•

Initial shelf life: 18 months, 18 months, and 9 months respectively, for the three
presentations

•

Proposed shelf life: 24 months for all presentations

•

Supporting Stability Data: 3 commercial batches manufactured at commercial scale
met the approved stability specifications

•

Stability Conditions: 5oC / Ambient R.H. and 25 oC / 60 % R.H.

•

Container-Closure System: bottle; 90cc HDPE bottle with 38mm Child resistant cap;
starter pack - PA/AL/PVC blister packs
6
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Regulatory Impact:

☒ Annual Reporting for US
☐ Notification
☒ Minor Variation for EU Type 1B and ‘Prior Approval’ for all other countries
Industry Case 2:
•

Product: Biological Drug Product

•

Initial shelf life: 24 months

•

Proposed Shelf Life: 36 months

•

Supporting Stability Data: 3 Commercial batches manufactured at commercial scale
met the approved stability specifications

•

Stability Conditions: 2-8 oC

•

Container-Closure System: 5.2 mL Lyophilized vial

•

Label Storage Condition: 2-8 oC, after reconstitution up to 12 hours at room
temperature (25 oC) and up to 24 hours at 2-8 oC

•

Regulatory Impact:

☒ Annual Reporting for US with approved stability protocol
☐ Notification
☒ Minor Variation for EU Type 1B and ‘Prior Approval’ for all other countries
Industry Case 3:
•

Product: Drug-Device Combination

•

Current Shelf Life: 18 months

•

Proposed Shelf Life: 24 months

•

Supporting Stability Data on: 3 commercial batches manufactured at commercial
scale met the approved stability specifications

•

Label Storage Conditions: US - store at 20-25 oC (See USP controlled room
temperature)/ EU - store below 25 oC

•

Container-Closure System: 15 mL bottle (60 doses); 30 mL bottle (120 doses)

•

Regulatory Impact:

☒ Annual Reporting for US with approved stability protocol
7
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☐ Notification
☒ Minor Variation for EU Type 1B and ’Prior Approval’ for all other countries
SCOPE
This paper applies to shelf-life extensions for commercial drug substances and drug
products (chemical, biological and biotechnological products). The principles and risk-based
approach described in this paper for shelf-life extensions of pharmaceutical products, are
intended to apply globally to all regulatory authorities.
INDUSTRY 1VQ POSTION FOR SHELF-LIFE EXTENSIONS OF PHARMACEUTICAL PRODUCTS
The International Council for Harmonization (ICH) has finalized Q12 “Technical and
Regulatory Considerations for Pharmaceutical Product Lifecycle Management” in November
2019. This guideline provides regulatory flexibility in post-approval changes to the product
or its manufacturing process based on latest product and process knowledge, soundscientific and risk-based approaches.
Shelf-life extensions for drug substance and drug product with the appropriate supporting
stability can be managed within the company’s Pharmaceutical Quality System (PQS)
leveraging the principles outlined in ICH Q9, Q10 and ICH Q12, and be reported to the
Regulatory Authorities within ICH, PIC/S and WHO member countries through Annual
Reports or Notifications without prior regulatory approval. This type of change is supported
by stability data that met the approved stability specifications and should not require prior
approval from the regulatory authorities. This will facilitate efforts to minimize drug
shortages and improve the on-time availability of products to patients worldwide.
The pharmaceutical industry’s position is to utilize the above-mentioned ICH guidelines for
the shelf-life extension based on acceptable risk without requiring prior regulatory approval.
This will allow the industry to avoid potential supply disruptions leading to drug shortages
and undue burden on patients. In addition, it will contribute towards meeting the ICH Q10
objectives of achieving product realization, establishing and maintaining a state of control,
and continual improvement.
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STANDARD RISK-BASED APPROACH
Figure 1 below [1] describes the risk-based approach for assessment of a PAC to shelf-life
extensions for pharmaceutical products. Application of this risk-based assessment utilizing
the latest product and process knowledge and supporting stability data, should
demonstrate that at a minimum, the shelf-life extension does not increase the risk to
product quality, efficacy and/or patient safety.
Figure 1: Risk-based Assessment of PACs and Determination of Regulatory Reporting
Category

Step 1 – Change Proposal

PAC

Change Mgmt.(CM)
System

High Level Impact Assessment of Change
NO
• Is there a potential impact to Quality, Safety
Efficacy (QSE) ?
• What might go wrong that may affect
QSE?
• Is there a potential legal / regulatory impact ?1

No impact on QSE AND
no legal / regulatory impact

Q9,
Q12

Step 2 – Change Evaluation
YES or MAYBE

(likely impact to ECs)

Q9

Assessment of risks to QSE
(based on current knowledge & Control Strategy)

Risk Assessment of
Change
(QRM tool/extent may vary)
HIGH

Q12

Assignment of regulatory reporting category :
• What is the legal / regulatory impact (e.g. to ECs )?
• Document justification for proposed reporting category

High risk
Prior-Approval

Step 3 – Change Implementation

MODERATE / LOW

Low/Moderate risk
Notification1

No submission/reporting required
Document with rationale within the
CM system and implement change

Change Implementation plan
(including risk controls identified)

Q9
Step 4 – Change Review & Closure

Change Review & Closure
(incl. Risk Review & Change Effectiveness)

1

Q9, Q10

Ongoing
Review/Monitoring
June 2019

(through PQS post change closure)

per local regulations

The following steps are completed to assess the impact and risks associated with shelf-life
extension:
Step 1: Change Proposal
When a PAC to shelf-life extensions of pharmaceutical products is proposed and entered
into the change management system, the potential Safety, Efficacy, Quality, Identity, Purity,
Potency (SEQIPP) and Legal/ Regulatory impact of the change is considered including
current control strategies. Utilizing existing product and process knowledge and stability
data, initial impact assessment indicates that:
9
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there is no potential SEQIPP risk associated with shelf-life extensions provided that
the stability data supporting the change is readily available, assessed and met the
approved stability specifications.

•

there is a potential regulatory impact due to the divergent local, national and
regional regulatory authorities’ requirements for the reporting category of the
change.

Step 2: Change Evaluation
A. Quality Risk Assessment: The initial impact assessment concluded that there is a
potential impact associated with the change, therefore, a quality risk assessment
should be performed for the shelf-life extension PAC.

An appropriate risk

assessment tool can be used to complete the risk assessment and should document
current controls. Stability testing laboratory, quality control and quality assurance
relevant subject matter experts should be involved in performing the risk
assessment. When assessing potential risks of the change, any potential impact
(direct or indirect) on the SEQIPP of the product should be considered, based on
current product/ process knowledge and the control strategy; some examples of risk
questions that should be considered to assess the risks associated with a change to
shelf-life extensions of pharmaceutical products include:
•

Can the change impact product safety?

•

Can the change potentially affect conformity of the product to current
specifications?

•

Can the change potentially affect the purity of the product?

•

Can the change potentially impact stability of the product?

B. Assignment of Regulatory Reporting Category: Consistent with ICH Q12 [3], it is
recommended that:
•

High-risk changes are categorized as prior-approval, and as such require
regulatory authority review and approval prior to implementation.

•

Moderate- to low-risk changes are communicated to the regulatory authority as
a formal notification, that takes place within a defined period before or after
implementation, according to regional regulatory requirements.
10
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The outcome of the risk assessment (performed in step 2A), and the available stability data,
should indicate that there is no impact to product safety, purity, stability or current
specifications. In such instances, a change to shelf-life extension for pharmaceutical
products can be deemed to be low risk with adequate risk controls, and therefore can be
managed as a notification with immediate effect for implementation through the
manufacturer’s PQS.
Steps 3 & 4: Change Implementation, Review and Closure
Change implementation, review and closure should be performed according to the change
management process. Outcomes of the impact and risk assessments should be integrated
into the overall change implementation plan. After implementation of the change, residual
risks should be assessed and managed to acceptable levels prior to change closure; any
unintended consequences or risks introduced as a result of the change should be evaluated,
documented and handled adequately through effectiveness verification mechanisms. In
case several changes are introduced at the same time or related to each other, the
manufacturer should assess cumulative effectiveness of the changes.
After change closure, relevant risk assessment tools/documents should be updated, and
post-effectiveness assessments documented in the PQS. Stability data trend analysis should
be used for the on-going review/monitoring of the risks associated with shelf-life
extensions.
The PIC/S Recommendation Paper on How to Evaluate/Demonstrate the Effectiveness of a
Pharmaceutical Quality System in relation to Risk-based Change Management” [6] provides
a practical checklist tool that can be used by the company to evaluate the effectiveness of
its risk-based change management process.
DEMONSTRATING EFFECTIVE MANAGEMENT OF SHELF-LIFE EXTENSION PAC WITHIN THE
PQS
The following risk-control elements have been considered for ensuring effective
management of shelf-life extensions within the PQS:
•

Any Out-of-Trend stability results are determined not to be product related

•

Statistical analysis shows the product remains within the approved stability
specifications throughout the proposed shelf life extension
11
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•

No confirmed out-of-specification stability results observed

•

No Formulation changes have been made for the applicable product

•

No critical changes to the manufacturing process

•

No critical changes to laboratory testing controls

•

No changes to the approved specification limits

•

Maintains ongoing follow-up stability programs on commercial batches

•

No final product market container-closure system changes

•

No changes to the stability-indicating analytical procedures and stability test
specifications for the product except possible addition of tests

The implementation of this change will be documented and tracked within the site change
management process. The outcomes of the risk assessments will be integrated into the
change implementation plan. Any residual risks will be assessed and managed to acceptable
levels prior to change closure. After change closure, relevant risk assessment documents
will be updated as part of post-effectiveness assessments.
CONCLUSION
This 1VQ position paper provides a standard and enhanced risk-based approach within the
framework of an effective PQS, that can be utilized by any company to gain regulatory
flexibility, reduce the burden and global complexity, and enable faster implementation of
shelf-life extensions for pharmaceutical products, without increasing risk to the patient
and/or product safety, efficacy, quality, identity, purity, and potency.
The benefits of practical application of the principles of ICH Q9, Q10 and Q12 as described in
this document are:
1. Continual improvement with timely (weeks or months vs years) implementation of
many PACs
2. Enhancing product availability and mitigating potential drug shortages
3. Focusing regulatory resources on PACs that may have a potential to impact product
quality as it relates to safety and efficacy
4. Reducing the regulatory approval burden for medium and low risk changes
5. Faster implementation of new knowledge and innovative technologies (if applicable
for this PAC example)
12
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About One-Voice-Of-Quality
Many post-approval changes require regulatory agency approval by individual countries
before implementation. Because of the global regulatory complexity, individual postapproval changes (PACs) usually take years for full worldwide approval even when they
reduce patient risk, improve compliance, or enhance the manufacturing process or test
methods.
Senior Quality Leaders (Chief Quality Officers and Heads of Quality) from more than 20
global pharmaceutical companies are speaking with “One-Voice-Of-Quality” (1VQ) to
advocate for an effective management of specific PACs that currently are handled as a priorapproval change in some countries, but where a standard science and risk-based approach
concludes that these should be downgraded to a notification or handled only in the
Pharmaceutical Quality System (PQS). This benefit would be a reduction of the
implementation timeline from years to months or weeks with no increased risk to patient
safety or product quality.
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